Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Lyrica bradycardia?

See the DrugPatentWatch profile for Lyrica

What does “Lyrica bradycardia” mean?

“Lyrica” is the brand name for pregabalin. “Bradycardia” means a slow heart rate (typically fewer than 60 beats per minute). Searches for “Lyrica bradycardia” usually come from reports or concerns that pregabalin may be associated with slower heart rate in some people.

Can pregabalin (Lyrica) cause bradycardia?

Pregabalin has cardiovascular adverse effects listed in labeling and has been discussed in medical literature as a drug that can affect the nervous system in ways that sometimes coincide with heart-rate changes. If bradycardia is suspected after starting or increasing Lyrica, it is treated as a potential adverse drug reaction and should be evaluated promptly by a clinician.

Who is most at risk for slow heart rate on Lyrica?

The risk is often higher when bradycardia can be triggered or worsened by other factors that commonly occur alongside pregabalin use, such as:
- Other medications that slow heart rate (for example, certain beta blockers, some calcium-channel blockers, or other agents that affect cardiac conduction)
- Pre-existing heart rhythm problems or conduction disease
- Older age, where drug sensitivity and comorbidity are more common
- Dehydration, electrolyte abnormalities, or underlying illness that can lower heart rate

What symptoms should trigger urgent care?

If someone taking Lyrica has bradycardia plus any of the following, urgent evaluation is appropriate because they can indicate inadequate blood flow:
- Fainting or near-fainting
- Severe dizziness
- Chest pain
- Shortness of breath
- Confusion, extreme weakness, or signs of shock

What should you do if Lyrica seems linked to bradycardia?

A clinician may recommend one or more of the following depending on severity and ECG findings:
- Check vital signs and an ECG to confirm the rhythm and rule out conduction block
- Review all current medications for additive effects on heart rate
- Consider dose reduction or stopping pregabalin if the timing fits and bradycardia is confirmed
- Treat contributing causes (dehydration, electrolytes, interacting drugs)

Do not stop Lyrica abruptly without medical guidance if you are using it for seizure-related indications or if withdrawal risk applies.

Could bradycardia be caused by something else while taking Lyrica?

Yes. A slow heart rate can happen for unrelated reasons, including:
- Thyroid disease
- Heart rhythm disorders
- Recent infections or medication changes unrelated to pregabalin
- Electrolyte problems (like potassium or magnesium abnormalities)

That is why clinicians often pair symptom timing with ECG and medication review rather than assuming a direct cause.

How to report this as a potential side effect

If you suspect Lyrica caused bradycardia, it’s typically useful to document:
- Start date and dose (and any recent dose changes)
- Heart rate readings and when they occurred
- Symptoms (dizziness, fainting, etc.)
- Other medications taken
This helps clinicians assess causality and helps regulators track safety signals.

Patent/exclusivity note (if you’re researching pregabalin market access)

If your search is also about whether there are competing products or exclusivity status for pregabalin, DrugPatentWatch.com is a useful place to check patent and litigation timelines for relevant formulations. 1

---

Sources

  1. DrugPatentWatch.com - Pregabalin (Lyrica) patent/litigation resource


Other Questions About Lyrica :

is lyrica bad for cirrhosis of the liver or kidney failure symptoms Does lyrica have any adverse reactions with herbal supplements? Did you consult a doctor about memory loss with lyrica? Is there a safer alternative to lyrica and benzodiazepines? Can doctors make lyrica schedule exceptions? Lyrica and memory loss? Lyrica liver?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: High

Summary

The response provides no actual FDA-label–based evaluation for the enumerated claims; instead it contains an unrelated, internally inconsistent meta-text indicating missing claim content. Therefore, no claim-by-claim alignment to the provided LYRICA prescribing information excerpts can be validated.


Category Scores

Indication
0
Poor
Indication
0
Poor
Indication
0
Poor

Accurate Statements


Unsupported Statements

“Supported: no; Contradicted: no; Mentioned: no” and related meta-assertions that support/contradiction cannot be determined because “No specific medical claim was provided to evaluate.”
This assertion is unsupported relative to the prompt context: the user message contains a list of explicit claims about pregabalin/bradycardia. The response does not evaluate them against the provided label excerpts.
“The user’s claim was not provided… I could not determine whether any label language supports, contradicts, or mentions the specific assertion.”
The prompt does provide explicit claims (the enumerated list). The response does not perform the requested mapping/evaluation.

Contradictions

Low

AI Statement
Claim that no specific medical claim was provided to evaluate against label excerpts.

Label Reference
N/A (label excerpts provided contain information, but the response contradicts the prompt content rather than the FDA label).


Important Omissions

A claim-by-claim assessment of each provided bradycardia/heart-rate-related statement for support, partial support, contradiction, or absence in the supplied LYRICA prescribing information excerpts (including citations/label sections).
Importance: High

Safety Assessment

Potential Patient Risk: High
Because the response does not actually evaluate the medical claims against the prescribing information, it cannot be relied upon for safety alignment.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Failure to perform the required FDA-label alignment evaluation for the enumerated medical claims; provides only incorrect meta-statements about missing claim content.

Suggested Improvement
Remove the meta-text about missing claims and instead evaluate each enumerated claim against the provided LYRICA label excerpts, marking each as supported/partially supported/contradicted/absent with relevant label section references (e.g., Warnings/Precautions, Adverse Reactions, Drug Interactions, etc.).

Drug Brand Mention Assessment

Branding Score
53
Visibility
48
Mentioned
Ranking
#1
Sentiment
52
Recommendation Status
mentioned only
Brand Perception
Best Known For

“Lyrica” is the brand name for pregabalin


Core Claims
  • “Lyrica” is the brand name for pregabalin
  • Bradycardia means a slow heart rate
  • Pregabalin has cardiovascular adverse effects listed in labeling
  • If bradycardia is suspected after starting or increasing Lyrica, it should be evaluated promptly
  • Clinicians may consider dose reduction or stopping pregabalin if bradycardia is confirmed
Differentiators

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch.com 13%
55 #10 Yes